The dispute was between two manufacturers of computer ... does not yet have marketing approval for the generic version in this country. With Lipitor such a huge earner for Pfizer — accounting ...

says Lipitor's sales grew by 40% in the first half of 2000; all by itself it accounted for 5.5% of the increase in prescription drug spending in 1999. The NIHCMF report links DTC ads with ...

Last year, Lipitor was the most popular branded drug in the U.S., with over 51 ... lower cholesterol have been a boon for pharmaceutical manufacturers, earning them more than $14 billion last ...

The “first industrial war” involved drug producers as much as weapons manufacturers ... and giving them a great deal of autonomy. "Lipitor...became the biggest-selling prescription medicine ...

By joining forces, Viatris became one of the largest generic drug manufacturers in the world ... 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, ...

In a recent government notification, retail prices of essential fixed combination drugs (FDCs) such as a combination of atorvastatin ... mentioned that manufacturers of scheduled formulations selling ...

Surveying issues ranging from cancer screening rates that haven’t recovered from the decline during the COVID-19 pandemic to low returns on investments for generic and biosimilar manufacturers ...

Women are more likely to have this side effect. When I see this in my patient, I will usually try a different type of statin drug. Atorvastatin is a “lipophilic” type of statin, meaning that ...

Women are more likely to have this side effect. When I see this in my patient, I will usually try a different type of statin drug. Atorvastatin is a “lipophilic” type of statin, meaning that ...

Women are more likely to have this side effect. When I see this in my patient, I will usually try a different type of statin drug. Atorvastatin is a “lipophilic” type of statin, meaning that ...

The lawsuit alleged the two companies conspired to delay the introduction of a generic version of Pfizer’s Lipitor that was produced by Ranbaxy. The combined settlement amount is $17 million.